秦亞東
摘要:目的? 分析多奈哌齊聯(lián)合阿米替林治療神經(jīng)衰弱伴發(fā)認知障礙患者的臨床效果。方法? 選取2018年1月~12月我院收治的神經(jīng)衰弱伴發(fā)認知障礙患者100例,隨機分為對照組和研究組,各50例。對照組予以阿米替林治療,研究組在對照組基礎(chǔ)上加用多奈哌齊治療,比較兩組患者睡眠障礙、認知障礙、生活質(zhì)量及不良反應(yīng)發(fā)生情況。結(jié)果? 研究組睡眠障礙、認知障礙評分低于對照組[(3.57±1.02)分vs(7.25±1.64)分,(3.61±0.93)分vs(7.13±1.55)分],差異有統(tǒng)計學意義(P<0.05);研究組總發(fā)生率為6.00%,低于對照組的24.00%,差異有統(tǒng)計意義(P<0.05);研究組軀體功能、心理功能、物質(zhì)生活、社會功能評分均高于對照組[(18.20±3.93)分vs(12.68±3.54)分,(18.59±3.62)分vs(13.77±3.32)分,(17.43±3.60)分vs(13.24±3.91)分,(17.89±3.62)分vs(12.53±3.78)分],差異有統(tǒng)計意義(P<0.05)。結(jié)論? 多奈哌齊聯(lián)合阿米替林治療神經(jīng)衰弱伴發(fā)認知障礙患者,可改善患者睡眠障礙、認知障礙,有效提高生活質(zhì)量,減少患者不良反應(yīng)的發(fā)生。
關(guān)鍵詞:多奈哌齊;阿米替林;神經(jīng)衰弱;認知障礙;睡眠障礙
中圖分類號:R749.1? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?文獻標識碼:A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI:10.3969/j.issn.1006-1959.2019.10.047
文章編號:1006-1959(2019)10-0144-03
Abstract:Objective? To analyze the clinical effects of donepezil combined with amitriptyline in the treatment of patients with neurasthenia and cognitive impairment. Methods? 100 patients with neurasthenia and cognitive impairment admitted to our hospital from January to December 2018 were randomly divided into control group and study group, 50 cases each. The control group was treated with amitriptyline. The study group was treated with donepezil on the basis of the control group. The sleep disorder, cognitive impairment, quality of life and adverse reactions were compared between the two groups. Results? The scores of sleep disorder and cognitive impairment in the study group were lower than those in the control group [(3.57±1.02) points vs (7.25±1.64)points, (3.61±0.93) points vs (7.13±1.55) points], and the difference was statistically significant (P<0.05); the total incidence rate of the study group was 6.00%, which was lower than that of the control group 24.00%,the difference was statistically significant (P<0.05). The physical function, psychological function, material life and social function scores of the study group were higher than the control group[(18.20±3.93) points vs (12.68±3.54) points, (18.59±3.62) points vs (13.77±3.32) points, (17.43±3.60) points vs (13.24±3.91) points, (17.89±3.62) points vs (12.53 ± 3.78) points, the difference was statistically significant (P<0.05). Conclusion? Donepezil combined with amitriptyline in the treatment of patients with neurasthenia and cognitive impairment can improve sleep disorders and cognitive impairment, improve quality of life and reduce adverse reactions.
參考文獻:
[1]王桂榮,黃華.鹽酸多奈哌齊聯(lián)合西酞普蘭治療青中年腦梗死患者抑郁及認知功能障礙臨床分析[J].中國實用神經(jīng)疾病雜志,2018,21(10):1083-1087.
[2]徐瑞華.鹽酸多奈哌齊治療神經(jīng)衰弱伴發(fā)認知障礙的臨床效果分析[J].中外醫(yī)學研究,2018,16(21):135-136.
[3]曹家駒,洪曉燕,馮上旭.多奈哌齊治療神經(jīng)衰弱伴發(fā)認知障礙的評價[J].藥品評價,2016,13(20):42-44.
[4]王偉.鹽酸多奈哌齊治療神經(jīng)衰弱伴發(fā)認知障礙的臨床效果評價[J].中國藥物與臨床,2017,17(5):741-743.
[5]湯朝輝.阿米替林聯(lián)合多奈哌齊對神經(jīng)衰弱并發(fā)認知障礙患者進行治療的效果研究[J].當代醫(yī)藥論叢,2017,15(8):25-26.
[6]馬雙喜,鄭智慧,喬豐爽.阿米替林聯(lián)合多奈哌齊治療神經(jīng)衰弱伴認知障礙患者的臨床效果分析[J].河南醫(yī)學研究,2016,25(4):697-698.
[7]袁堂坤.多奈哌齊在神經(jīng)衰弱伴發(fā)認知障礙治療中的應(yīng)用分析[J].中國衛(wèi)生標準管理,2015(9):257-258.
[8]吳福有.阿米替林聯(lián)合多奈哌齊治療神經(jīng)衰弱伴認知障礙患者的臨床效果分析[J].心理醫(yī)生,2017,23(21):97-98.
[9]馬俊霞.不同劑量多奈哌齊對輕中度老年癡呆患者認知功能的干預(yù)作用[J].中國實用神經(jīng)疾病雜志,2016,19(23):51-53.
[10]潘早霞.多奈哌齊治療神經(jīng)衰弱伴發(fā)認知障礙的臨床效果分析[J].中國社區(qū)醫(yī)師,2016,32(13):89-90.
[11]周莎莎.鹽酸多奈哌齊聯(lián)合高壓氧治療腦卒中后血管性認知障礙的效果觀察[J].中國實用神經(jīng)疾病雜志,2016,19(19):63-64.
[12]沈雷.高壓氧聯(lián)合鹽酸多奈哌齊治療輕中度血管性認知障礙患者的療效觀察[J].中國藥物經(jīng)濟學,2016,11(9):92-93.
[13]馬立華.鹽酸多奈哌齊片聯(lián)合銀杏葉片治療老年血管性認知障礙分析[J].中國實用神經(jīng)疾病雜志,2015,18(4):102-103.
收稿日期:2019-2-18;修回日期:2019-2-28
編輯/杜帆